Quel est le prix pour GlycoNex Incorporation (4168)

Le prix pour GlycoNex Incorporation (4168) est $0.71865803

Quelle est la capitalisation boursière pour GlycoNex Incorporation (4168)

La capitalisation boursière pour GlycoNex Incorporation (4168) est $80.86M

GlycoNex Incorporation (4168) Ratio P/S

GlycoNex Incorporation, based in New Taipei City, Taiwan, specializes in developing innovative cancer therapeutics. The company achieves this by leveraging advanced glycosphingolipid antigen and human monoclonal antibody technologies. Its robust pipeline for solid tumors features several investigational antibody drugs. These include GNX102, a humanized monoclonal antibody currently in Phase 1 clinical trials; GNX201, an antibody candidate undergoing lead optimization; and GNX202, which is in preclinical development. Additionally, GNX203 and GNX204 are antibody drugs presently in the target validation stage. Beyond oncology, GlycoNex is also advancing other therapeutic agents. This includes SPD (Denosumab), a humanized IgG2 antibody in preclinical stages for both osteoporosis and oncology indications. Another key asset is SEA (Aflibercept), a vascular endothelial growth factor (VEGF) binding fusion protein, currently undergoing lead optimization for its potential use in ophthalmology and oncology. GlycoNex was established in 2001.

Année	Ratio P/S	Changez
Pas assez de données pour les dates fournies.

Année

Ratio P/S

Changez

Pas assez de données pour les dates fournies.

Entreprise	Ratio P/S	Différence de Ratio P/S	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
Moderna, Inc. MRNA.US	11.28	-	US
CSL Limited CSL.AX	2.95	-	AU
Lonza Group AG LONN.SW	-	-	CH

Entreprise

Ratio P/S

Différence de Ratio P/S

Pays